MedTrace Logo

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07441642 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2026-05-12

No results posted yet for this study

Summary

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Conditions

  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

DRUG

FWY003

FWY003 arm participants will receive a specific dose of FWY003

DRUG

Placebo

Placebo arm participants will receive placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2029-08-21
Completion
2029-08-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07441642 on ClinicalTrials.gov